LBRX — LB Pharmaceuticals Inc Stock Price, Chart & AI Report

Positive Feb 27, 2026 • 16:44 UTC Benzinga • Prnewswire

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

ATAI DFTX GHRS LBRX psychedelic biotechnology Phase 3 trials treatment-resistant depression generalized anxiety disorder

Sentiment note

Initiated Phase 2 ILLUMINATE-1 trial for bipolar depression with 320 patients, Phase 2 schizophrenia data showed statistically significant benefits, secured $100M private placement funding, and positioned as potential first benzamide antipsychotic approved in the U.S.

Positive Feb 5, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals Inc (LBRX) announced a $100 million private placement of common stock and pre-funded warrants at $21.17 per share from institutional investors. The company plans to use proceeds to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, with closing expected on February 6, 2026.

LBRX private placement capital raise LB-102 Phase 2 trial major depressive disorder institutional investors biopharmaceutical

Sentiment note

The company successfully secured $100 million in funding from reputable institutional investors, demonstrating investor confidence. The capital will advance their lead product candidate LB-102 into Phase 2 trials for additional indications, representing meaningful progress in their clinical development pipeline.

Positive Jan 6, 2026 • 12:00 UTC GlobeNewswire Inc. • Lb Pharmaceuticals, Inc

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President of Corporate Affairs and Lindsay Beaupre as Senior Vice President of People and Culture. Both executives bring extensive experience from leading biopharmaceutical and financial services companies. The appointments come as the company advances LB-102, its novel benzamide candidate, into Phase 3 trials for schizophrenia and Phase 2 trials for bipolar depression.

LBRX leadership appointments corporate affairs people and culture LB-102 schizophrenia bipolar depression clinical development

Sentiment note

The company is strengthening its executive leadership team with experienced hires from reputable organizations (Lyell Immunopharma, Prothena, Johnson & Johnson, Vertex Pharmaceuticals, Immunogen). This demonstrates organizational growth and confidence in advancing LB-102 through critical clinical development phases. The appointments support the company's strategic expansion during a transformative period.